Axsome Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company developing novel therapies for the management of central nervous system, or CNS, disorders for which there are limited treatment options. Our approach to developing differentiated, new therapies is based on use of novel mechanisms of action, and innovative and proprietary medicinal chemistry and formulation technologies. Our core CNS portfolio includes four product candidates, AXS-05, AXS-07, AXS-12 and AXS-14 which are being developed for multiple indications.

Investor Relations

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Featured Events